Loading...
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
BACKGROUND: Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient’s survival. However, BRAF-mutated CRC...
Saved in:
| Published in: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7027203/ https://ncbi.nlm.nih.gov/pubmed/32066410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6586-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|